Precosa

Quick links to important sections

Precosa

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Precosa

What is Precosa? Defining the Biological Antidiarrhoeal Agent

Property Description
Active ingredient Saccharomyces boulardii CNCM I-745
Form Capsule and powder for suspension
Pharmacological class Antidiarrhoeal micro-organism
Common use Stabilizing bowel function and resolving digestive disturbances
Origin Natural origin (Non-pathogenic yeast)

Precosa is a specialized medicine classified as a biological antidiarrhoeal agent and a probiotic that functions locally within the gastrointestinal tract. This medicine belongs to the pharmacological class of Antidiarrhoeal micro-organisms. Unlike conventional chemical antidiarrhoeal agents, Precosa is a drug-microorganism preparation recognized for its role in microbial gut support. It is defined by its non-systemic action, focusing on reinforcing the balance and integrity of the gut lining.


Composition and Forms: The Role of Saccharomyces boulardii

The active ingredient in Precosa is the unique, non-pathogenic yeast strain Saccharomyces boulardii CNCM I-745, which is of natural origin. The preparation is comprised of lyophilized viable cells of this yeast, meaning they are freeze-dried to maintain their activity until consumption. This yeast-based composition provides a key differentiating feature from most bacterial-based probiotics. It is administered via the oral route in pharmaceutical forms, which typically include a hard capsule and a powder for oral suspension contained within a sachet. This makes the product suitable for various patient groups, including children, who may benefit from the sachet presentation.


Key Difference: How Precosa Supports Gut Health

The core principle of Precosa's action is its ability to support the stability of the gut microflora and reinforce the intestinal barrier function through localized activity. The active component possesses properties that help to normalize gut function. This distinguishes it from agents that function by physical absorption or slowing motility. Precosa's profile is defined by its ability to stabilize the intestinal environment, positioning it as a live biotherapeutic product that helps address the underlying disturbances of the gut, contributing to the overall resolution of digestive disturbances.

What side effects are possible with Precosa?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety characteristics of Precosa (Saccharomyces boulardii CNCM I-745), strictly based on government regulatory information.


Adverse Reaction Classification

Adverse reactions documented in official product labeling are classified by their estimated frequency of occurrence:

Frequency Examples of Officially Listed Reactions
Common Flatulence
Rare Allergic reactions, pruritus (itching), urticaria (hives), angioedema
Very Rare Anaphylactic reaction or shock
Not Known Fungemia, sepsis (documented in post-marketing surveillance)

The officially recognized System-Organ-Classes affected primarily include Gastrointestinal Disorders, Immune System Disorders, and Skin and Subcutaneous Tissue Disorders.


Serious Safety Considerations

The most serious adverse events documented are fungemia (the presence of yeast in the bloodstream) and sepsis. These are very rare risks that have been reported, specifically in the following populations mentioned in official regulatory warnings:

  • Immunocompromised patients
  • Critically ill patients
  • Patients with a Central Venous Catheter (CVC)

This serious risk profile highlights the need for specific high-level safety constraints documented in the labeling. The medicine should be used with caution, and its use is typically avoided concurrently with systemic or oral antifungal agents. Furthermore, strict procedural precautions are required when handling the product near patients with a CVC to prevent potential airborne contamination.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information often indicates that traditional, dose-dependent overdose signs and symptoms for Precosa (Saccharomyces boulardii CNCM I-745) are not formally documented, with the overdose section sometimes noted as “Not applicable.” The critical safety guidance instead focuses on the risk of severe systemic infection associated with the use of this live micro-organism.

Serious Outcomes and High-Risk Populations

The most severe, life-threatening outcomes reported are fungemia (yeast in the bloodstream) and sepsis, which have been fatal in some cases. This risk is primarily confined to specific, highly vulnerable patient populations:

  • Patients with a central venous catheter.
  • Critically ill patients.
  • Immunocompromised patients.

Signs of this severe complication often include pyrexia (fever) which may be accompanied by positive blood cultures for Saccharomyces strains.

Required Emergency Actions

Immediate medical attention is necessary if signs of a systemic infection, such as high fever or sepsis, occur. Procedural management documented in regulatory safety literature for these severe events requires:

  1. Cessation of treatment with Saccharomyces boulardii.
  2. Administration of antifungal treatment.
  3. Removal of the catheter when deemed necessary.

Urgent medical help must be sought due to the life-threatening nature of fungemia and sepsis in these susceptible patients.

Therapeutic Uses of Precosa

Precosa is generally used to help manage various gastrointestinal conditions, relevant in contexts involving acute or unstable symptom patterns. The active ingredient is applied in clinical settings for short-term symptomatic assistance with several diarrheal conditions.


What Precosa Treats: Main Uses and Benefits

Precosa is relevant for easing symptoms that interfere with daily comfort across conditions characterized by periods of heightened symptoms. It is commonly used to help manage symptoms linked to antibiotic-associated diarrhea, traveler’s diarrhea, and acute diarrhea in children. In these scenarios, the medication provides support that helps ease the overall symptom burden. It is applied when supportive symptom management is appropriate, assisting patients with maintaining functional stability during episodes of heightened discomfort.

The overall intent of the supportive use is to assist with maintaining functional stability when symptoms are more noticeable. The use is appropriate in clinical settings that involve acute or unstable symptom patterns, contributing to improved day-to-day comfort.

Quick Fact: Relief for Acute Diarrhea

Regulatory References

  1. Health Canada's Natural Health Products Database

Eligibility and Restrictions for Use

Who Can and Cannot Use Precosa?

The population eligibility for Precosa (Saccharomyces boulardii CNCM I-745) is strictly defined by regulatory documents, primarily due to the safety profile associated with a live yeast preparation.

Absolute Contraindications (Who Must Not Use)

Use of Precosa is strictly contraindicated in several high-risk populations due to the potential for fungemia (yeast bloodstream infection). The medicine must not be administered to patients who are critically ill or immunocompromised, or those with a central venous catheter (CVC) or indwelling central line. Additionally, it is contraindicated for patients with a known hypersensitivity or allergy to the active substance or yeast. The medicine must not be used concurrently with oral or systemic antifungal drugs, as these agents inactivate the active ingredient.

Age-Group and Special Population Eligibility

The use of Precosa is generally established for adults and children. Caution is advised for use in older adults due to a documented, potentially increased risk of fungal infection. Use is not recommended for very small premature infants due to a lack of sufficient safety data. Regulatory documents state that the medicine is generally permitted for use during both pregnancy and breastfeeding.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Precosa contains the non-systemic biological agent Saccharomyces boulardii CNCM I-745, a live yeast. Due to its nature, its interaction profile is focused on functional antagonism and specific safety-related restrictions, rather than typical pharmacokinetic interactions.

Official Regulatory Documentation

Interaction Type Restriction or Outcome
Contraindicated Combinations Antifungal medicinal products (systemic or oral)
Pharmacodynamic Interaction Antifungal agents (e.g., fluconazole, ketoconazole) reduce the viability and activity of the live yeast in the gut.
Pharmacokinetic Interactions None documented with CYP enzymes or drug transporters (e.g., P-gp), reflecting its non-systemic action.

Interaction-Related Restrictions and Considerations

The primary interaction-related restriction is the avoidance of co-administration with oral or systemic antifungal medicinal products. This is necessary because the antifungal effect would functionally inactivate the biological component of Precosa, leading to reduced activity.

Regulatory authorities also cite a critical population-specific constraint regarding safety. Precosa is strictly contraindicated for use in high-risk patient populations. This includes critically ill patients, immunocompromised individuals, and those with a central venous catheter (CVC), due to the officially documented risk of developing fungemia (a fungal blood infection). No mandatory timing separation rules are explicitly defined in official labels for co-administered products.

Mechanism of Action

How Precosa Works: Mechanism of Action

Precosa's action is entirely peripheral and local to the gastrointestinal lumen and mucosa. The active yeast, Saccharomyces boulardii, employs a multi-modal mechanism. Primarily, it secretes a mathbf54 kDa serine protease enzyme that acts as an inhibitor by hydrolyzing and inactivating bacterial toxins, such as Clostridium difficile Toxins A and B. The yeast also directly binds to pathogens, preventing their adherence to epithelial receptors.

Intracellularly, it modulates host cell signaling by influencing pro-inflammatory pathways, including mathbfNF -kappamathbfB and MAP Kinase. This action affects the production of cytokines and supports the integrity of tight junctions between enterocytes. The resulting physiological consequences include reduced intestinal permeability and the modification of the signal that drives excessive fluid secretion.

Additionally, the presence of the yeast influences microbial population dynamics, promoting the competitive exclusion of pathogens. It also activates the mucosal immune system by stimulating the production of local Secretory Immunoglobulin A (sIgA), influencing localized regulatory feedback.

Dosage and Administration Information

How to Use Precosa: Official Administration Guidelines

The use of Precosa (Saccharomyces boulardii CNCM I-745) involves specific instructions focusing on the principles of administration. The medication is delivered exclusively via the oral route, consistent with its function as an antidiarrhoeal micro-organism intended to act locally within the gastrointestinal tract.


Dosing and Frequency

Standard adult and pediatric regimens commonly specify a dose of 250 mg to 500 mg, to be administered twice daily (BID). The typical duration of use is short-term, intended to support acute episodes, and may correspond to the length of concurrent therapy, such as an entire course of antibiotics. Since the product is not systemically absorbed, there is typically no specified need for dose adjustment in cases of renal or hepatic impairment.


Preparation and Administration

Precosa is available as a hard capsule (250 mg) and a powder for oral suspension (250 mg or 500 mg). Capsules may be swallowed whole, or the contents can be opened and mixed with liquid or soft food. The powder must be dissolved in a liquid or mixed with food immediately before ingestion. It is a critical instruction that the product must not be mixed with any hot substances above 50 C or alcohol, as these substances compromise the viability of the live yeast cells. Furthermore, in clinical environments, it is advised not to open the product near patients with central venous catheters to prevent procedural contamination. The medication may be taken with or without food.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Precosa


Evidence for Use in Preventing Antibiotic-Associated Diarrhea (AAD)

Research has extensively examined the use of Precosa alongside courses of antibiotics. These studies, primarily Randomized Controlled Trials (RCTs) and comprehensive meta-analyses, were structured to explore if administering Precosa during or after antibiotic treatment was studied to assess the risk of developing AAD, a condition characterized by fluctuating or episodic manifestations. Study populations included both children (pediatric) and adults receiving various antibiotics.

Multiple pooled analyses of these trials described patterns related to the incidence of AAD development in diverse groups of patients receiving antibiotics. Research highlights changes measured during the study period, indicating that this approach was studied in relation to temporary physiological imbalance during and shortly after antibiotic exposure.

Evidence for Use in Managing Acute Diarrhea

Controlled trials was studied for their relevance in conditions involving periods of heightened symptoms, specifically acute diarrhea. The research primarily focused on children diagnosed with acute gastroenteritis, with studies exploring its use alongside standard oral rehydration therapy. Studies measured outcomes describing episodic or acute changes, such as the duration of diarrhea and changes in stool frequency over a short period.

In the populations observed, research highlights changes measured during the study period. Findings across various trials described patterns in the observed duration of increased stool frequency, although the evidence is heavily weighted toward the pediatric population.


What Remains Uncertain in the Research Landscape

The evidence base has limitations. Long-term effects are not fully established, as follow-up durations were often limited to the acute post-treatment phase. Data for older adults as a distinct subgroup remains insufficient, and the efficacy may vary depending on the specific infectious agent prevalent in Traveler's Diarrhea trials.

Key Studies & References

  1. Efficacy of Saccharomyces boulardii for traveler's diarrhea: a meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Precosa (FAQ)

Q: Are there certain foods or drinks I need to avoid while taking Precosa?

The official product information states that the product must not be mixed with alcohol or with any liquids or foods that are hot (above 50 C). These conditions can destroy the live active yeast cells in the medicine. Otherwise, official information states the product can generally be mixed with cold or room-temperature beverages or soft foods, such as applesauce or yogurt.

Q: Is Precosa considered an antibiotic or an antiviral?

Precosa is classified by global health authorities as an Antidiarrhoeal micro-organism, which is a specific type of probiotic that utilizes a live yeast strain. This distinguishes it from chemically based medicines. It is not classified as an antibiotic or an antiviral medicine.

Q: Why is Precosa sometimes referred to by a different name?

Precosa is the specific brand name given to the product by the manufacturer. The active component, Saccharomyces boulardii CNCM I-745, is the generic or scientific name used across all regulatory documents. The product may be known by this scientific name or other brand names in different regions.

Q: What happens if I forget to take a dose of Precosa?

Official instructions describe the procedure for a missed dose: it is taken as soon as it is remembered, unless it is nearly time for the next scheduled dose. If it is almost time for the next dose, the instruction is to skip the missed one. The guidance emphasizes that the dose should not be doubled.

Q: Is Precosa safe to take for an extended period of time?

Studies have examined the safety profile of the product for up to 15 months of continuous use, and it is described as possibly safe for most adults in this timeframe. However, the official research follow-up durations are often limited, meaning long-term safety beyond that period is not fully established.

Q: Is there a generic version of Precosa available?

Precosa is a brand name. The active ingredient, Saccharomyces boulardii, is a generic designation that is widely available under various other trade names and as an over-the-counter (OTC) supplement.

Q: What should I do if I accidentally take two doses of Precosa?

Taking an extra dose may cause gastrointestinal symptoms like gas or constipation, which typically resolve upon discontinuing use or reducing the amount taken. Official guidance recommends contacting a poison control center or seeking immediate medical help for a known overdose or if severe symptoms occur.

Q: Do I need a prescription to get Precosa?

Precosa, or products containing the same active ingredient, is widely available as an over-the-counter (OTC) product in capsule or powder form in many markets. Its regulatory classification (drug versus supplement) may vary by country.

Q: Why do official documents mention certain precautions with Precosa?

Precautions are documented primarily due to the rare but serious risk of fungemia, which is a fungal blood infection. This risk has been reported specifically in critically ill or immunocompromised patients, or those with a central venous catheter. These warnings are documented due to the risk profile associated with the product.

Q: Does Precosa contain any common allergens like gluten or lactose?

The full list of inactive ingredients varies by specific product brand and form. However, regulatory warnings specify that caution is warranted for people with lactose intolerance, as some formulations of the product may contain lactose.

Q: Does Precosa affect the way blood pressure medications work?

Official product information notes a lack of documented pharmacokinetic (PK) interactions, which reflects its non-systemic action. However, external drug interaction checkers list potential minor or moderate interactions with common drug classes like some blood pressure medications. Official guidance recommends sharing a complete list of all medications with a healthcare provider.

Q: Is Precosa associated with any effects on the liver or kidneys?

Regulatory information typically does not list specific adverse effects associated with liver or kidney toxicity. Since Precosa is not systemically absorbed, a dose adjustment is usually not specified for patients with existing renal or hepatic impairment.

Q: Is Precosa likely to interact with commonly used over-the-counter pain relievers?

Official drug interaction checkers indicate minor or unknown interactions with commonly used over-the-counter pain relievers, such as ibuprofen or acetaminophen. Official guidance recommends providing a healthcare provider with a complete list of all co-administered medications.

Q: Can I take Precosa if I'm taking herbal supplements?

Official regulatory guidance specifies that patients should provide a complete list of all medicines, non-prescription drugs, herbs, and dietary supplements to a healthcare professional. The interaction profile with the wide variety of herbal supplements is not fully detailed in general product labeling.

Q: Can Precosa cause tiredness or fatigue?

Officially documented common side effects for Precosa focus primarily on flatulence and mild gastrointestinal upset. Tiredness or fatigue are not typically listed in the official labeling as common or frequent adverse reactions.

Q: Is a metallic taste in the mouth a possible side effect of Precosa?

Metallic taste is not listed in the official regulatory documentation as a common or frequent adverse reaction associated with the product. Officially recognized adverse events mainly concern gastrointestinal and rare immune system disorders.

Q: Can Precosa be taken at the same time as my daily vitamin?

Drug interaction checkers list minor or unknown interactions with several common vitamins. As with any combination of products, official patient information recommends informing a healthcare provider of all vitamins and supplements being used concurrently.

Q: Is it normal to feel slightly nauseous when first taking Precosa?

Officially documented common side effects for the product focus primarily on flatulence. Nausea or stomach upset are not listed in the official labeling as common or frequent adverse reactions, but mild gastrointestinal symptoms may be reported.

Q: Does taking Precosa require any special monitoring by a doctor?

No routine laboratory tests or special monitoring procedures are generally specified in the product labeling. However, the use of Precosa alongside certain drugs may necessitate monitoring, as determined by a healthcare provider.

Q: Is Precosa commonly used outside of my country?

The active ingredient, Saccharomyces boulardii CNCM I-745, is registered and commonly used under different brand names in many regions worldwide. This includes countries regulated by the EMA (Europe) and other global health authorities.

Q: Is Precosa known to cause headaches?

Headaches are not listed in the official regulatory documentation as a common or frequent adverse reaction associated with the product. Adverse event reporting focuses on gastrointestinal symptoms.

Q: Does Precosa cause weight changes?

Weight changes are not listed in the official regulatory documentation as a common or frequent adverse reaction associated with the product. Documented adverse reactions primarily affect the gastrointestinal system.

Q: What official body approved Precosa for use?

The product is reviewed and approved by national regulatory bodies in various regions worldwide, such as the FDA, EMA, or Health Canada. Its classification as a prescription drug, an over-the-counter medicine, or a dietary supplement is determined by these national authorities.

How should Precosa be stored and disposed of?

The official regulatory documentation outlines specific requirements for storing and disposing of Precosa (Saccharomyces boulardii CNCM I-745) to ensure the viability of the live active ingredient.

Storage Requirements

The medicine must be stored at a temperature below 30°C and away from humidity. It must be kept in the original container and out of the sight and reach of children.

Stability and Handling

To preserve the product's stability, Precosa must not be mixed with very hot (over 50°C), iced, or alcoholic liquids during preparation. A critical handling rule requires that the sachets or capsules must not be opened in the rooms of critically ill or immunocompromised patients to prevent the risk of airborne contamination.

Disposal

Unused or expired product must not be disposed of via wastewater or household waste. Disposal must be carried out in accordance with local regulatory requirements, typically by returning it to a pharmacist.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Precosa found in:

A-Z Index: